DCVMN CEO Visits BioMinhai: Paving the Way for Vaccine Collaboration

On March 19, 2025, Dr. Rajinder Suri, CEO of the Developing Countries Vaccine Manufacturers Network(DCVMN) visited BioMinhai, located at No.35 Simiao Road, Daxing District, Beijing, China, for in-depth exchanges on cooperation and development in the field of vaccines. 

Dr. Rajinder Suri, CEO of DCVMN, gave a detailed introduction to DCVMN. DCVMN is an international organization dedicated to promoting the development of vaccine industry in developing countries, bringing together many vaccine manufacturers to contribute to global vaccine supply through resource sharing and cooperation. Dr. Rajinder Suri highlighted the important role of DCVMN in global vaccines and the broad prospects for working with BioMinhai. 

Mr. Miao Xiang, President of Kangtai Group, and Ms. Zhang Qian (Chloe), Director General, International BU, warmly welcomed DCVMN. They detailed BioMinhai's development history, technical strength, and achievements in vaccine development and production. As a leading vaccine enterprise in China, BioMinhai has been dedicated to the R&D and production of innovative vaccines and contributed to the global public health. Mr. Miao said that BioMinhai looked forward to further cooperation with DCVMN to promote the development of the vaccine industry. 

DCVMN team visited BioMinhai's new plant workshop. Visitors were impressed by modern production equipment, advanced production technology and strict quality control system. The professional strength of BioMinhai in the field of vaccine production has been fully demonstrated and laid a solid foundation for future cooperation. 

The visit of the DCVMN team is not only a vital opportunity for BioMinhai to communicate and cooperate with the International Vaccine Organization, but also an crucial step for Chinese vaccine enterprises to go to the international market. In the future, BioMinhai will continue to adhere to the concept of open cooperation and work with global vaccine enterprises to contribute more to global public health.